

**InnoVenture Iowa, LLC**  
Investment Committee Meeting  
Wednesday, July 16, 2025  
7:00 a.m.

**Public Webinar Access:**

[NEW InnoVenture Iowa Investment Committee Meeting: Pipeline Review | Meeting-Join | Microsoft Teams](#)

**I. Committee Chair**

*Gary Weihs*

- A. Welcome
- B. Roll Call Action
- C. Approval of June 11 Meeting Minutes Action

**II. Public Comment Period**

A public comment period for the full meeting will be held at this time to accommodate visitors. This period is limited to 10 minutes.

**Closed Session [Iowa Code sections 15.118, 21.5(1)a and 22.7]\*\***

Discussion of Information Contained in Startup Due Diligence Process

**III. Pipeline Review**

*Micah Walker*

- A. Startup Overviews Discussion
- B. Q&A with Committee Discussion

**Open Session [Iowa Code sections 15.118, 21.5(1)a and 22.7]\*\***

Reopen Meeting for Formal Adjournment

**VII. Adjourn**

Action

**Investment Committee Members:**

Anita Norian, Gary Weihs, Clayton Nevins, Leigh Parker, Martina Bockenstedt

**Non-Voting Attendees:**

Steve Brody – CEO, BioConnect Iowa;  
Safiya Lee-Evans – Program Manager;  
Micah Walker – Investment Analyst

INNOVENTURE IOWA, LLC  
666 Walnut Street, Suite 1285  
Des Moines, Iowa 50309  
Phone: (515) 657-7138



**Please Note:**

The meeting will convene no earlier than stated above, but may begin later, depending on the length of earlier meetings. Agenda items may be considered out of order at the discretion of the Chair for each meeting. If you require accommodation to participate in this public meeting, call (515) 657-7138 to make your request. Please notify us as soon as possible in advance of the meeting.

**\*\*The InnoVenture Iowa Investment Committee**, if a quorum is present, may go into closed session pursuant to Iowa Code sections 21.5(1)a, 15.118, 22.7.3, 22.7.6 and 22.7.8 to review and discuss records InnoVenture Iowa is required to treat as confidential under Iowa law. This includes confidential business and financial information about applicants and industrial prospects with which the Fund is currently negotiating.